Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer

PeerJ

article

David Jacobson¹  Kathleen Moore³  Camille Gunderson³  Michelle Rowland³  Rita Austin¹  Tanvi Prasad Honap¹  Jiawu Xu⁵  Christina Warinner⁷  Krithivasan Sankaranarayanan²  Cecil M. Lewis Jr¹ 

[1] Department of Anthropology, University of Oklahoma;Laboratories of Molecular Anthropology and Microbiome Research ,(LMAMR), University of Oklahoma;Stephenson Cancer Center, University of Oklahoma Health Sciences Center;Saint Luke’s Hospital of Kansas City;Ragon Institute;Harvard Medical School, Harvard University;Department of Anthropology, Harvard University;Department of Microbiology and Plant Biology, University of Oklahoma

关键词: Lactobacillus;    Escherichia;    16S rRNA;    Platinum-based chemotherapy;   

DOI  :  10.7717/peerj.11574

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

Many studies investigating the human microbiome-cancer interface have focused on the gut microbiome and gastrointestinal cancers. Outside of human papillomavirus driving cervical cancer, little is known about the relationship between the vaginal microbiome and other gynecological cancers, such as ovarian cancer. In this retrospective study, we investigated the relationship between ovarian cancer, platinum-free interval (PFI) length, and vaginal and gut microbiomes. We observed that Lactobacillus-dominated vaginal communities were less common in women with ovarian cancer, as compared to existing datasets of similarly aged women without cancer. Primary platinum-resistance (PPR) disease is strongly associated with survivability under one year, and we found over one-third of patients with PPR (PFI < 6 months, n = 17) to have a vaginal microbiome dominated by Escherichia 24 months, n = 23) patient had an Escherichia-dominated microbiome. Additionally, L. iners was associated with little, or no, gross residual disease, while other Lactobacillus1 cm gross residual disease. In the gut microbiome, we found patients with PPR disease to have lower phylogenetic diversity than platinum-sensitive patients. The trends we observe in women with ovarian cancer and PPR disease, such as the absence of Lactobacillus and presence of Escherichia in the vaginal microbiome as well as low gut microbiome phylogenetic diversity have all been linked to other diseases and/or pro-inflammatory states, including bacterial vaginosis and autoimmune disorders. Future prospective studies are necessary to explore the translational potential and underlying mechanisms driving these associations.

【 授权许可】

CC BY